申请人:Neurogen Corporation
公开号:US06369053B1
公开(公告)日:2002-04-09
Disclosed are compounds of the formula:
or pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof,
wherein R1, R2, R3, X, Q1 and Q2 are defined herein,
which compounds are ligands for neurokinin receptors, in particular NK-3 receptors, and are therefor useful in the treatment of a wide range of diseases or disorders including, but not limited to depression, anxiety, psychosis, obesity, pain, Parkinson's disease, Alzheimer's disease, neurodegenerative diseases, movement disorders, respiratory diseases, inflammatory diseases, neuropathy, immune disorders, migraine, biliary disfunction, and dermatitis.
本发明涉及以下公式的化合物:或其药学上可接受的盐或药学上可接受的溶剂,其中R1、R2、R3、X、Q1和Q2的定义如下,这些化合物是神经激肽受体的配体,特别是NK-3受体,因此可用于治疗广泛的疾病或疾病,包括但不限于抑郁症、焦虑症、精神病、肥胖症、疼痛、帕金森病、阿尔茨海默病、神经退行性疾病、运动障碍、呼吸系统疾病、炎症性疾病、神经病、免疫障碍、偏头痛、胆道功能障碍和皮炎。